# Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Source: https://onco.cc/trials/nct06834672/  
OnCo record `nct06834672` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing IBI354 in ovarian cancer, active and no longer recruiting.

## Summary

Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer is a phase 3 interventional study registered as NCT06834672, led by Innovent Biologics (Suzhou), and active but no longer recruiting on the registry. Official title: A Multicenter, Randomised, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Planned enrolment is 450 participants (estimated). The study started in 2025-03-17 and primary completion is expected in 2027-12-28. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06834672
- Phase: 3
- Setting: A Multicenter, Randomized, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Sponsor: Innovent Biologics (Suzhou)
- Enrolled: 450

## Sources

- ClinicalTrials.gov NCT06834672: https://clinicaltrials.gov/study/NCT06834672

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [IBI354](https://onco.cc/drugs/ibi354/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/nct06834672.json